Medivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostrox PR...
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study PR...
Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan PR...
Medivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated...
Medivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runway PR Newswire STOCKHOLM, Dec. 6, 2023...
Medivir to present at the Carlsquare Equity Research Investor Day PR Newswire STOCKHOLM, Dec. 6, 2023 STOCKHOLM, Dec. 6, 2023 /PRNewswire/...
Bulletin from Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Dec. 1, 2023 STOCKHOLM, Dec. 1, 2023 /PRNewswire/...
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC PR...
Medivir to present at the Redeye Life Science Day PR Newswire STOCKHOLM, Nov. 22, 2023 STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB...
Medivir to present at the Erik Penser Bank Company Event PR Newswire STOCKHOLM, Nov. 21, 2023 STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- Medivir AB...
Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA PR...
Notice of Extraordinary General Meeting in Medivir AB (publ) PR Newswire STOCKHOLM, Nov. 7, 2023 STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- The...
MEDIVIR AB - INTERIM REPORT JANUARY - SEPTEMBER 2023 PR Newswire STOCKHOLM, Oct. 27, 2023 STOCKHOLM, Oct. 27, 2023 /PRNewswire/ -- Updated data...
Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday PR Newswire STOCKHOLM, Oct. 25, 2023...
Nomination Committee of Medivir appointed PR Newswire STOCKHOLM, Oct. 23, 2023 STOCKHOLM, Oct. 23, 2023 /PRNewswire/ -- Medivir AB (Nasdaq...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.